Litcius/Paper detail

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

Yuankai Shi, Yanqiu Zhao, Sheng Yang, Jianying Zhou, Liangming Zhang, Gongyan Chen, Jian Fang, Bo Zhu, Xingya Li, Yongqian Shu, Jianhua Shi, Rongsheng Zheng, Donglin Wang, Huiqing Yu, Jianan Huang, Zhixiang Zhuang, Gang Wu, Longzhen Zhang, Zhongliang Guo, Michael N. Greco, Xiao Li, Yu Zhang

2022Journal of Thoracic Oncology27 citationsDOI

Topics & Concepts

MedicineInternal medicineLeukopeniaPharmacokineticsT790MConfidence intervalAdverse effectNeutropeniaPopulationPhases of clinical researchToxicityGastroenterologyOncologyEpidermal growth factor receptorCancerGefitinibEnvironmental healthLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesAdvanced Breast Cancer Therapies
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study | Litcius